Immune Checkpoint Inhibitors
Cross-source consensus on Immune Checkpoint Inhibitors from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Benefits
Risks & contraindications
Highlighted claims
- ICI therapy works by blocking inhibitory pathways that tumours use to evade immune detection. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- Nivolumab blocks PD-1 and restores effector T-cell function. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- Ipilimumab blocks CTLA-4 to enhance T-cell priming and proliferation. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- First-line nivolumab plus ipilimumab was associated with better overall survival and progression-free survival than dual targeted therapy. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- ICI causes a higher burden of severe treatment-related toxicity than dual targeted therapy. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials